EXETER, N.H.--(BUSINESS WIRE)--
Vapotherm, Inc. today announced the publication of a key prospective,
multi-center, controlled, order-randomized crossover trial. The study
demonstrates that using the IntellO2 automated oxygen
controller module helped clinicians maintain neonates in the
physician-prescribed oxygen saturation range significantly better than
manual control alone.
The results were published by Reynolds and colleagues in the Archives
of Disease in Childhood: Fetal and Neonatal Edition, entitled
“Randomised crossover study of automated oxygen control for preterm
infants receiving nasal High Flow.” The data show that trained staff
were able to keep the babies’ oxygen saturation in the target range 49%
of the time with manual controls alone. When using the IntellO2
module staff was able to maintain the babies in range 80% of the time.
“We are very pleased with these results. This study shows the ability of
the IntellO2 to help clinicians maintain premature babies in
the prescribed target pulse oxygenation range. We now have strong
evidence that when compared to manual control, using the IntellO2
improves the ability to keep babies within target saturation range,”
said Joe Army, CEO of Vapotherm. “We are excited to continue development
of this unique technology to help clinicians control oxygenation, since
both too much and too little oxygen have important clinical
consequences. We see applications for this technology initially in the
neonate patient population, and eventually for oxygen vulnerable adult
patients as well.”
The IntellO2 works with the Precision Flow system, using
pulse oximetry to monitor blood oxygen saturation and adjust inspired
oxygen concentration settings accordingly. It utilizes a unique
proprietary software algorithm designed to work with Hi-VNI®
Technology. This study was conducted on a prototype device, and the
system is currently not commercially available.
Vapotherm, Inc. (NYSE:VAPO) is a global medical technology
company based in Exeter, New Hampshire that is focused on the
development and commercialization of its proprietary Hi-VNI Technology
products that are used to treat patients of all ages suffering from
respiratory distress. The company develops innovative, comfortable,
non-invasive technologies for respiratory support of patients with
chronic or acute breathing disorders. Over 1.5 million patients have
been treated with Vapotherm Hi-VNI Technology. For more information,
visit www.vapotherm.com.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20181204005067/en/
Lise Halpern
VP Marketing
603-658-0011
LHalpern@vtherm.com
Source: Vapotherm, Inc.